Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Neoplasms

In brief

The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.

Key facts

Study ID

NCT00628251

Run by

AstraZeneca

People needed

97

Starts

2008-07-30

Expected to finish

2018-09-19

Last updated by the study team

2019-12-05

Who can join

Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Advanced ovarian cancer with positive BRCA1 or BRCA2 status
• Progressive or recurrent disease after platinum-based chemotherapy
• Measurable disease by RECIST

You may not qualify if…

• Previous anthracycline treatment
• Brain metastases
• Less than 28 days since last treatment used to treat the disease
• Considered a poor medical risk due to a serious uncontrolled disorder

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — San Francisco, California, United States
• Research Site — Boca Raton, Florida, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — New York, New York, United States
• Research Site — Houston, Texas, United States
• Research Site — East Melbourne, Australia
• Research Site — Melbourne, Parkville, Australia
• Research Site — Randwick, Australia
• Research Site — Leuven, Belgium
• Research Site — Cologne, Germany
• Research Site — München, Germany
• Research Site — Haifa, Israel
• Research Site — Ramat Gan, Israel
• Research Site — Tel Aviv, Israel
• Research Site — Szczecin, Poland
• Research Site — Barcelona, Spain
• Research Site — Hospitalet deLlobregat, Spain
• Research Site — Lund, Sweden
• Research Site — Cambridge, United Kingdom
• Research Site — Edinburgh, United Kingdom
• Research Site — London, United Kingdom
• Research Site — Manchester, United Kingdom
• Research Site — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.